natgillin/translations-raw huggingface dataset:
Posaconazole AHCL must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval (see sections 4.3 and 4.5). 
Zdravila Posakonazol AHCL se ne sme uporabljati skupaj z zdravili, ki so substrati CYP3A4 in za katere je znano, da podaljšajo interval QTc (glejte poglavji 4.3 in 4.5).
- a “statin” such as simvastatin, atorvastatin or lovastatin used to treat high cholesterol. 
- katerega od statinov, na primer simvastatina, atorvastatina ali lovastatina, ki se uporabljajozazdravljenje visokega holesterola.
Posaconazole tablets are the preferred formulation to optimize plasma concentrations and generally provide higher plasma drug exposures than posaconazole oral suspension. 
Posakonazol v obliki tablet jeprimernejša oblika za optimiziranje plazemske koncentracije in na splošno zagotavlja večjo plazemsko izpostavljenost zdravilu kot peroralna suspenzija posakonazola.
- Candida albicans: S ≤0.06 mg/L, R >0.06 mg/L - Candida tropicalis: S ≤0.06 mg/L, R >0.06 mg/L - Candida parapsilosis: S ≤0.06 mg/L, R >0.06 mg/L 
Mejnevrednosti EUCAST MIC za posakonazol [občutljivi(S-susceptible); odporni (R-resistant)]: - Candida albicans:S≤0,06 mg/l, R> 0,06 mg/l - Candida tropicalis:S≤0,06 mg/l, R> 0,06 mg/l - Candida parapsilosis:S≤0,06 mg/l, R> 0,06 mg/l
• If you have any further questions, ask your doctor, pharmacist or nurse. 
• Če imate dodatna vprašanja, se posvetujte z zdravnikom,farmacevtomali medicinsko sestro.
electrolyte imbalance, anorexia, decreased appetite, hypokalaemia, hypomagnesaemia 
neravnovesje elektrolitov, anoreksija, zmanjšanje apetita,hipokaliemija, hipomagneziemija
For patients with acute myelogenous leukemia or myelodysplastic syndromes, prophylaxis with Posaconazole AHCL should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per mm3. 
Pri bolnikih z akutno mieloično levkemijo ali mielodisplastičnimi sindromi je treba profilakso z zdravilom Posakonazol AHCL začeti več dni pred pričakovanimpojavomnevtropenije innajtrajaše 7 dnipozvečanju števila nevtrofilcev nad
Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole). 
Sočasniuporabiposakonazola in rifabutina se je treba izogibati, razen če korist za bolnika odtehta tveganje (glejte zgoraj za učinke rifabutina na plazemsko koncentracijo posakonazola).
Effects of posaconazole on other medicinal products 
Vpliviposakonazola na druga zdravila
Posaconazole is absorbed with a median tmax of 3 hours (fed patients). 
Absorpcija Posakonazolse absorbira z medianovrednostjo tmax 3 ure (nahranjeni bolniki).
Tabulated list of adverse reactions Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000); not known. 
V okviru organskih sistemovso neželeni učinki navedeniz naslednjimi kategorijami pogostnosti: zelopogosti (≥1/10), pogosti (od ≥1/100 do < 1/10), občasni (od ≥1/1.000 do < 1/100), redki (od
Do not adapt your dose yourself before consulting your doctor or change your treatment regime. 
Brezposvetovanja zzdravnikom si odmerka ali režima zdravljenja ne smete spreminjati sami.
The effect of posaconazole on CYP3A4 substrates in patients might be somewhat lower than that observed in healthy volunteers, and is expected to be variable between patients due to the variable posaconazole exposure in patients. 
Učinek posakonazola na substrate CYP3A4 je lahko pri bolnikih nekolikomanjši kot pri zdravih prostovoljcih in mogoče je pričakovati, da se od bolnika dobolnika razlikuje zaradi različne stopnje izpostavljenosti posakonazolu.
Posaconazole had no effect on fertility of male rats at doses up to 180 mg/kg (1.7 times the 400 mg twice daily regimen based on steady-state plasma concentrations in healthy volunteers) or female rats at a dose up to 45 mg/kg (2.2 times the 400-mg twice daily regimen). 
Posakonazol ni vplival na plodnost podganjih samcev v odmerkih do 180 mg/kg (1,7-krat 400 mg režim dvakrat na dan, ki temelji na plazemskih koncentracijah v stanju dinamičnega ravnovesja pri zdravih prostovoljcih) ali podganjih samic v odmerku do 45 mg/kg (2,2-krat 400 mg režim dvakrat na dan).
As HIV protease inhibitors are CYP3A4 substrates, it is expected that posaconazole will increase plasma levels of these antiretroviral agents. 
Zaviralci proteaze HIV so substrati CYP3A4, zato se pričakuje, da bo posakonazol povečal plazemskokoncentracijo teh protiretrovirusnih zdravil.
Posaconazole AHCL can increase the amount of these medicines in the blood which may lead to a severe decrease in blood flow to your fingers or toes and could cause damage to them. 
Zdravilo Posakonazol AHCL lahko poveča koncentracijo teh zdravilv krvi; to lahko zelo zmanjša dotok krvi v prste rok in nog in lahko povzroči njihovo okvaro.
Posaconazole AHCL contains approximately 1.75g of glucose per 5mLof suspension. 
Zdravilo Posakonazol AHCL vsebuje približno 1,75 g glukoze na 5 ml suspenzije.
Overall efficacy of posaconazole oral suspension at the end of treatment for invasive aspergillosis in comparison to an external control group 
Skupna učinkovitost peroralnesuspenzije posakonazola ob koncu zdravljenjainvazivneaspergiloze v primerjavi z zunanjokontrolnoskupino Peroralnasuspenzijaposakona zola
- if you are taking: terfenadine, astemizole, cisapride, pimozide, halofantrine, quinidine, any medicines that contain “ergot alkaloids” such as ergotamine or dihydroergotamine, or a “statin” such as simvastatin, atorvastatin or lovastatin 
- čejemljete:terfenadin, astemizol, cisaprid, pimozid, halofantrin, kinidin, katero koli zdravilo, ki vsebuje alkaloide ergot(na primer ergotamin ali dihidroergotamin)ali kakšen statin, naprimer simvastatin, atorvastatin ali lovastatin.
Posaconazole is also available as 100 mg gastro-resistant tablet and 300 mg concentrate for solution for infusion. 
Posakonazol je na voljo tudi v obliki 100-miligramskih gastrorezistentnih tabletin 300-miligramskega koncentrata za raztopino za infundiranje.
The effect of posaconazole on sirolimus in patients is unknown, but is expected to be variable due to the variable posaconazole exposure in patients. 
Učinek posakonazola na sirolimus pri bolnikih ni znan, vendar jetrebapričakovati, da jespremenljiv zaradi spremenljive izpostavljenosti posakonazolu med bolniki.
Following administration of 800 mg per day of posaconazole as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12 patients 8 - 17 years of age (776 ng/mL) were similar to concentrations from 194 patients 18 - 64 years of age (817 ng/mL). 
Po uporabi800 mg posakonazola na dan v deljenih odmerkih za zdravljenje invazivnih glivnih okužbje bila povprečna najmanjša plazemska koncentracija pri 12 bolnikih, starih od 8 do 17 let (776 ng/ml), podobnakotpri 194 bolnikih, starih od 18 do 64 let(817 ng/ml).
No further increases in exposure were observed when doses above 800 mg daily were administered to patients and healthy volunteers. 
Pri dajanju odmerkov nad 800 mg na dan bolnikom in zdravim prostovoljcem nisoopažali nobenega nadaljnjega povečanja izpostavljenosti zdravilu.
To improve absorption of posaconazole, whenever possible it should be taken during or immediately after food or a nutritional drink (see section 3 “How to take Posaconazole AHCL”). 
Zdravilo Posakonazol AHCL skupaj s hrano in pijačo Da se izboljša absorpcija posakonazola ga, kadar koli je le mogoče, vzemite med ali takoj po jedi ali zaužitju prehranskega dopolnila v obliki napitka (glejte poglavje 3 “Kako jemati zdravilo Posakonazol AHCL”).
The primary packaging is an amber glass bottle (Type III) closed with a child-resistant and tamper evident polypropylene cap. 
Primarna ovojnina je steklenička iz rjavega stekla (tipa III), zaprta z za otrokevarno polipropilenskozaporko, ki je ni mogoče odpreti brez vidnih znakov odprtja.
The pharmacokinetics of posaconazole are linear following single and multiple dose administration of up to 800 mg when taken with a high fat meal. 
Farmakokinetikaposakonazola je linearna po enkratnem in večkratnem dajanju odmerkov do 800 mg,
Alternatively, patients who can tolerate food or a nutritional supplement may take 400 mg (10 mL) twice a day during or immediately following a meal or nutritional supplement. 
200 mg(5 ml) štirikrat na dan. Bolniki, ki prenašajo hrano aliprehranske dodatke, lahko vzamejo 400 mg (10ml) dvakrat na danmed ali takoj po jedi ali prehranskem dodatku.
If you develop severe diarrhoea or vomiting (being sick) while taking Posaconazole AHCL, talk to your doctor, pharmacist or nurse straight away, as this may stop it from working properly. 
Če se med jemanjem zdravila Posakonazol AHCL pojavita huda driska ali bruhanje (slabost), se takoj posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, kajti lahko preprečita pravilno delovanje zdravila.
Posaconazole inhibits the enzyme lanosterol 14α-demethylase (CYP51), which catalyses an essential step in ergosterol biosynthesis. 
Posakonazolzaviraencimlanosterol-14α-demetilazo(CYP51),kikatalizira eno od ključnih stopenj vbiosintezi ergosterola.
Non-Interchangeability between posaconazole tablets and Posaconazole AHCL Oral Suspension The tablet and oral suspension are not to be used interchangeably due to the differences between these two formulations in frequency of dosing, administration with food and plasma drug concentration achieved. 
Medsebojna nezamenljivost tablet posakonazola in Posakonazol AHCL peroralne suspenzije Tablet in peroralne suspenzije se ne sme uporabljati medsebojno zamenljivo zaradi razlik med oblikama v pogostnosti odmerjanja, razlik pri uporabi s hrano in razlik v doseganju plazemskih koncentracij zdravila.
The effect of co-administration with posaconazole on plasma levels of CYP3A4 substrates may also be variable within a patient, unless posaconazole is administered in a strictly standardised way with food, given the large food effect on posaconazole exposure (see section 5.2). 
Učinek sočasne uporabe posakonazola na plazemske koncentracije substratov CYP3A4 se lahkorazlikuje tudi pri posameznembolniku, razen če prejme posakonazol na strogo standardiziran način s hrano, glede na velik vplivhrane na izpostavljenost posakonazolu (glejte poglavje 5.2).
In rabbits, posaconazole was embryotoxic at exposures greater than those obtained at therapeutic doses. 
Pri kuncih je bilposakonazol embriotoksičen pri izpostavljenostih, večjih od izpostavljenosti, doseženih sterapevtskimiodmerki.
Patients were treated with posaconazole or fluconazole oral suspension (both posaconazole and fluconazole were given as follows: 100 mg twice a day for 1 day followed by 100 mg once a day for 13 days). 
Bolnikeso zdravili s posakonazolom ali s peroralno suspenzijo flukonazola (tako posakonazol kot flukonazol soodmerjalinanaslednjinačin:100 mg dvakrat na dan 1 dan,potempa100 mg enkrat na dan 13 dni).
White to off-white free flowing suspension. 
FARMACEVTSKA OBLIKA peroralna suspenzija bela do belkasta dobro tekoča suspenzija
In addition, posaconazole oral suspension (200 mg or 400 mg) prolonged the mean terminal half-life of midazolam from approximately 3-4 hours to 8-10 hours during co-administration. 
Poleg tega jeperoralnasuspenzija posakonazola (200 mg ali 400mg) med sočasno uporabo podaljšala povprečniterminalnirazpolovničas midazolama s približno 3 do 4ure na 8 do 10 ur.
Therefore, inhibitors (e.g. verapamil, ciclosporin, quinidine, clarithromycin, erythromycin, etc.) or inducers (e.g. rifampicin, rifabutin, certain anticonvulsants, etc.) of these clearance pathways may increase or decrease posaconazole plasma concentrations, respectively. 
eritromicin, itd.) ali induktorji (npr. rifampicin, rifabutin, določeni antikonvulzivi, itd.) teh poti izločanja povečajo ali zmanjšajo koncentracije posakonazola v plazmi.
Proportion (%) of patients with proven/probable IFIs On-treatment periodb 
Vrednost p Odstotek (%) bolnikov z dokazanimi oziroma verjetnimi invazivnimi glivnimi okužbami Obdobjezdravljenjab
Do not switch between taking Posaconazole tablets and posaconazole oral suspension without talking to your doctor or pharmacist because it may result in a lack of efficacy or an increased risk of adverse reactions. 
Ne preidite na jemanje tablet posakonazola,čejemljete peroralno suspenzijo posakonazola, in obratno, ne da bi seposvetovali z zdravnikom ali farmacevtom, saj lahko pride do pomanjkanja učinkovitosti alipovečanegatveganjazaneželeneučinke.
In heart transplant patients on stable doses of ciclosporin, posaconazole oral suspension 200 mg once daily increased ciclosporin concentrations requiring dose reductions. 
Pri bolnikih s presajenim srcem, ki prejemajo stabilne odmerke ciklosporina,jeperoralnasuspenzijaposakonazola v odmerku 200mg enkrat na dan povečala koncentracijo ciklosporina, tako da jebilopotrebno zmanjšanje njegovega odmerka.
The mean duration of therapy was 80 days for posaconazole and 77 days for fluconazole. 
Zdravljenje s posakonazolom je trajalo povprečno80 dni in s flukonazolom77 dni.
Therefore, trough concentrations that fall in the upper part of the usual therapeutic range should be targeted and careful attention should be paid to clinical signs and symptoms, laboratory parameters and tissue biopsies. 
Zatomorabiticiljna najnižja koncentracija sirolimusa v zgornjem delu običajnega terapevtskega razponain posebno pozornost je treba namenitikliničnimznakomin simptomom,laboratorijskimparametromin tkivnimbiopsijam.
The addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated with increases in plasma bilirubin levels. 
Dodatek posakonazola med zdravljenjem z atazanavirjem oziroma zatazanavirjem in ritonavirjem je bilpovezan s povečanjemkoncentracijebilirubina vplazmi.
11 of 24 patients who had proven or probable fusariosis were successfully treated with posaconazole oral suspension 800 mg/day in divided doses for a median of 124 days and up to 212 days. 
11 od 24 bolnikov, ki so dokazano ali verjetno imeli fuzariozo, so uspešno zdravili s peroralnosuspenzijo posakonazola 800 mg/dan v deljenih odmerkih.Srednjavrednosttrajanjazdravljenjajebila 124 dni, zdravljenjepajelahkotrajalo do 212 dni.
Co-administration of posaconazole with CYP3A4 substrates may result in large increases in exposure to CYP3A4 substrates as exemplified by the effects on tacrolimus, sirolimus, atazanavir and midazolam below. 
Sočasna uporaba posakonazola in substratov CYP3A4lahko zelo poveča izpostavljenost tem substratom, kot kažejo spodajopisaniučinki na takrolimus,sirolimus, atazanavir in midazolam.
Echocardiography revealed no indication of cardiac decompensation in a repeat dose safety pharmacology study in rats at a systemic exposure 1.4-fold greater than that achieved therapeutically. 
Vfarmakološki študiji varnosti ponavljajočih se odmerkov ehokardiografija pri podganah nipokazalaznakov srčne dekompenzacije pri sistemski izpostavljenosti, ki je bila 1,4-krat večja od terapevtskodosežene.
Following single-dose administration of posaconazole oral suspension, there was no effect of mild and moderate renal impairment (n=18, Cl cr ≥ 20 mL/min/1.73 m2) on posaconazole pharmacokinetics; therefore, no dose adjustment is required. 
Po enkratnemodmerku peroralne suspenzije posakonazolablagain zmernaokvara ledvic (n = 18,očistekkreatinina ≥20 ml/min/1,73 m2)nista vplivali na farmakokinetiko posakonazola, zatoprilagoditevodmerka ni potrebna.
Clinical success rates in Oropharyngeal Candidiasis Endpoint 
Klinična uspešnost pri orofaringealni kandidozi
At exposures lower than those obtained at therapeutic doses in humans, posaconazole caused skeletal variations and malformations, dystocia, increased length of gestation, reduced mean litter size and postnatal viability. 
Priizpostavljenostih,manjšihod izpostavljenosti, doseženih s terapevtskimiodmerkipričloveku,jeposakonazol povzročil spremembe skeleta in malformacije, distocijo, podaljšanje gestacije, manjšepovprečno število mladičev inmanjšo postnatalno življenjsko sposobnost.
The mean duration of therapy was 29 days for posaconazole and 25 days for fluconazole/itraconazole. 
Zdravljenje s posakonazolomjetrajalo povprečno 29 dniin s flukonazolom/itrakonazolom25 dni.
Calcium channel blockers metabolised through CYP3A4 (e.g. diltiazem, verapamil, nifedipine, nisoldipine) 
Zaviralcikalcijevihkanalčkov, ki se presnovijo s CYP3A4 (npr. diltiazem, verapamil, nifedipin,
Therefore, reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options. 
Azolskiantimikotiki,vključno s posakonazolom, najbodo zato rezerviraniza bolnike, ki prejemajo alkaloid vinke, vključnoz vinkristinom, in ki nimajo alternativnih možnosti protiglivnega zdravljenja.
Posaconazole has been shown in vitro to be active against the following microorganisms: Aspergillus species (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), Candida species (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus. 
Dokazano je,daposakonazol invitro deluje proti naslednjim mikroorganizmom:vrstiAspergillus(Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), vrstiCandida (Candidaalbicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata,
Reporting of suspected adverse reactions 
Poročanjeo domnevnih neželenih učinkih
FLU = fluconazole; ITZ = itraconazole; POS = posaconazole. 
FLU = flukonazol; ITZ = itrakonazol; POS = posakonazol a:
This medicine works by killing or stopping the growth of some types of fungi that can cause infections. 
Tozdravilo deluje tako, da uniči nekatere vrste gliv, ki lahko povzročajo okužbe, ali ustavi njihovorast.
Children Posaconazole AHCL should not be used in children (17 years of age and younger). 
Otroci ZdravilaPosakonazol AHCL senesmeuporabljatipriotrocih(starih17letali manj).
Based on pharmacokinetic data in 10 of these paediatric patients, the pharmacokinetic profile appears to be similar to patients ≥ 18 years of age. 
Na podlagifarmakokinetičnihpodatkovpri10 od teh pediatričnih bolnikov jefarmakokinetičniprofil videtipodoben kot pri bolnikih, starih ≥18 let.
What Posaconazole AHCL is and what it is used for What you need to know before you take Posaconazole AHCL How to take Posaconazole AHCL Possible side effects 
Kaj je zdravilo Posakonazol AHCL in za kaj ga uporabljamo Kajmorate vedeti, preden boste vzeli zdravilo Posakonazol AHCL Kako jemati zdravilo Posakonazol AHCL Možni neželeni učinki
Ask your pharmacist how to throw away medicines you no longer use. 
načinuodstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
Midazolam and other benzodiazepines metabolised by CYP3A4 
Midazolam in drugibenzodiazepini, ki se presnovijo s CYP3A4
Sixteen patients 8-17 years of age were treated with posaconazole oral suspension 800 mg/day in a study for invasive fungal infections (Study 0041). 
Šestnajst bolnikov, starih od 8 do 17 let,so v študiji invazivnih glivnih okužb zdravili s peroralnosuspenzijo posakonazola v odmerku 800 mg/dan (študija0041).
If these medicinal products are co-administered, careful monitoring of full blood counts and adverse reactions related to increased rifabutin levels (e.g. uveitis) is recommended. 
V primeru sočasne uporabe jepriporočljivo skrbno spremljanje celotne krvne slikeinneželenihučinkov,povezanih s povečanokoncentracijo rifabutina (npr. uveitisa).
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujtezzdravnikom, farmacevtom alimedicinsko sestro.
The expiry date refers to the last day of that month. 
Rokuporabnosti zdravila se izteče na zadnji dan navedenegameseca.
Refractory invasive fungal infections (IFI)/patients with IFI intolerant to 1st line therapy 
Rezistentne invazivne glivneokužbe/bolniki z rezistentnoglivno okužbo, ki ne prenašajozdravljenja 1. izbora
The safety of posaconazole tablet has been assessed in 336 patients and healthy volunteers enrolled in clinical trials. 
Varnost tablet posakonazola so ocenili pri 336 bolnikih in zdravih prostovoljcih, vključenih v klinična preskušanja.Varnostniprofil tablet je podoben varnostnemu profilu peroralnesuspenzije.
As observed with other azole antifungal agents, effects related to inhibition of steroid hormone synthesis were seen in repeated-dose toxicity studies with posaconazole. 
Kot so opažali tudi pri drugih azolskih antimikotikih, so v študijah toksičnosti ponavljajočih se odmerkov posakonazola opaziliučinke, povezane zzaviranjemsinteze steroidnih hormonov.
Based on the available data in 16 of these paediatric patients, the safety profile appears to be similar to patients ≥ 18 years of age. 
Napodlagirazpoložljivihpodatkovza 16 od teh pediatričnih bolnikov jevarnostniprofil zdravila videti podoben kot pri bolnikih, starih ≥18 let.
Treatment of azole-susceptible Oropharyngeal Candidiasis (OPC) A randomised, evaluator-blind, controlled study was completed in HIV-infected patients with azolesusceptible oropharyngeal candidiasis (most patients studied had C. albicans isolated at baseline). 
Randomizirana, s "slepim ocenjevalcem"kontrolirana študija je bila opravljena pri bolnikih, okuženihz virusomHIV, ki so imeli na azole občutljivo orofaringealno kandidozo (pri večini bolnikov v tejštudijisonazačetkuštudijeizolirali C. albicans).
Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1): - Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; - Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; - Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; - Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. 
Zdravilo Posakonazol AHCL peroralna suspenzija je indicirano za zdravljenje naslednjih glivnih okužb pri odraslih (glejte poglavje 5.1): - invazivne aspergiloze pri bolnikih z okužbo, odporno na amfotericin B ali itrakonazol, ter pri bolnikih, ki ne prenašajo teh zdravil, - fuzarioze pri bolnikih z okužbo, odporno na amfotericin B, ter pri bolnikih, ki ne prenašajo amfotericina B, - kromoblastomikoze in micetoma pri bolnikih z okužbo, odporno na itrakonazol, ter pri bolnikih,
INFORMATION IN BRAILLE Posaconazole AHCL 
PODATKI V BRAILLOVI PISAVI Posakonazol AHCL
Gender The pharmacokinetics of posaconazole are comparable in men and women. 
Spol Farmakokinetika posakonazola jepri moškihin ženskah primerljiva.
The majority (377/600, [63 %]) of patients included had Acute Grade 2 or 3 or chronic extensive (195/600, [32.5%]) GVHD at study start. 
Ključni sekundarni opazovani dogodekjebila pojavnostdokazanihoziromaverjetnih invazivnihglivnihokužb med obdobjemzdravljenja (odprvegaodmerkadozadnjegaodmerkaproučevanegazdravila + 7 dni).Večina(377/600,[63%]) vštudijo vključenih bolnikov je imela na začetku študije akutno GVHD stadija 2 ali 3 ali kronično obsežno GVHD (195/600, [32,5 %]).
Co-administration of posaconazole with H2 receptor antagonists should be avoided if possible. 
Sočasni uporabi posakonazola in antagonistov receptorjevH2sejetreba izogibati, če je le mogoče.
acute renal failure, renal failure, blood creatinine increased 
akutnaodpovedledvic,odpovedledvic,zvišanjeravnikreatinina v krvi